TR200102034T2 - Anti kanser aşılaması için antikorların kullanılması - Google Patents

Anti kanser aşılaması için antikorların kullanılması

Info

Publication number
TR200102034T2
TR200102034T2 TR2001/02034T TR200102034T TR200102034T2 TR 200102034 T2 TR200102034 T2 TR 200102034T2 TR 2001/02034 T TR2001/02034 T TR 2001/02034T TR 200102034 T TR200102034 T TR 200102034T TR 200102034 T2 TR200102034 T2 TR 200102034T2
Authority
TR
Turkey
Prior art keywords
antibodies
anti cancer
cancer vaccination
vaccination
relates
Prior art date
Application number
TR2001/02034T
Other languages
English (en)
Turkish (tr)
Inventor
Eckert Helmut
Loibner Hans
Original Assignee
Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag filed Critical Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag
Publication of TR200102034T2 publication Critical patent/TR200102034T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TR2001/02034T 1999-01-13 2000-01-12 Anti kanser aşılaması için antikorların kullanılması TR200102034T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH5199 1999-01-13

Publications (1)

Publication Number Publication Date
TR200102034T2 true TR200102034T2 (tr) 2001-11-21

Family

ID=4178206

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02034T TR200102034T2 (tr) 1999-01-13 2000-01-12 Anti kanser aşılaması için antikorların kullanılması

Country Status (28)

Country Link
US (3) US7691372B2 (https=)
EP (2) EP1140168B1 (https=)
JP (1) JP4774551B2 (https=)
KR (1) KR100771752B1 (https=)
CN (1) CN1188169C (https=)
AT (2) ATE219687T1 (https=)
AU (1) AU768515B2 (https=)
CA (1) CA2360382C (https=)
CZ (1) CZ302801B6 (https=)
DE (2) DE50000243D1 (https=)
DK (2) DK1230932T3 (https=)
EE (1) EE05474B1 (https=)
ES (2) ES2236375T3 (https=)
HK (1) HK1044487B (https=)
HR (1) HRP20010526A2 (https=)
HU (1) HU226150B1 (https=)
ID (1) ID30223A (https=)
IL (2) IL144265A0 (https=)
IS (1) IS5998A (https=)
MX (1) MXPA01007148A (https=)
NO (1) NO329917B1 (https=)
NZ (1) NZ512722A (https=)
PL (1) PL201533B1 (https=)
PT (2) PT1230932E (https=)
SI (2) SI1230932T1 (https=)
SK (1) SK286627B6 (https=)
TR (1) TR200102034T2 (https=)
WO (1) WO2000041722A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226150B1 (en) * 1999-01-13 2008-05-28 Igeneon Krebs Immuntherapie Use of antibodies for anticancer vaccination
AT410172B (de) 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
US7759464B2 (en) 2004-07-14 2010-07-20 Greenovation Biotech Gmbh N-glycosylated antibody
EP1618890B1 (en) * 2004-07-20 2010-10-06 Altropus Gmbh Use of antibodies in a very low dose for the vaccination against cancer
CN103285392A (zh) * 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
CN101969966B (zh) 2007-12-07 2013-05-08 努特里希亚公司 用于尘螨变态反应的双歧杆菌
AU2010217120B2 (en) 2009-02-24 2014-11-20 Novartis Ag Methods for identifying immunobinders of cell-surface antigens
US8887373B2 (en) 2012-02-24 2014-11-18 Covidien Lp Vessel sealing instrument with reduced thermal spread and method of manufacture therefor
US20140276968A1 (en) * 2013-03-14 2014-09-18 Ethicon, Inc. Applicator systems for surgical fasteners
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341281C (en) * 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5270202A (en) * 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO1997005597A1 (en) * 1995-07-31 1997-02-13 Litton Systems Canada Limited Flat panel pixel array incorporating photoconductive switches
EP0857176A1 (en) * 1995-10-25 1998-08-12 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
US6235280B1 (en) * 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
IL121041A0 (en) * 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
US6274143B1 (en) * 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
IL139700A (en) * 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer
HU226150B1 (en) * 1999-01-13 2008-05-28 Igeneon Krebs Immuntherapie Use of antibodies for anticancer vaccination
WO2001087233A2 (en) * 2000-05-16 2001-11-22 New York University Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions and method of use thereof

Also Published As

Publication number Publication date
KR20010101446A (ko) 2001-11-14
NO20013093D0 (no) 2001-06-21
SI1140168T1 (en) 2002-10-31
HK1044487B (zh) 2005-09-16
HK1044487A1 (en) 2002-10-25
US20100233178A1 (en) 2010-09-16
EE05474B1 (et) 2011-10-17
US20070224202A1 (en) 2007-09-27
DE50009240D1 (de) 2005-02-17
PL201533B1 (pl) 2009-04-30
CA2360382C (en) 2011-05-24
HU226150B1 (en) 2008-05-28
JP2002534481A (ja) 2002-10-15
ID30223A (id) 2001-11-15
ATE219687T1 (de) 2002-07-15
PL364747A1 (en) 2004-12-13
NZ512722A (en) 2003-07-25
US8444974B2 (en) 2013-05-21
CZ20012581A3 (cs) 2002-01-16
EE200100366A (et) 2002-10-15
JP4774551B2 (ja) 2011-09-14
EP1230932A3 (de) 2003-11-26
ES2236375T3 (es) 2005-07-16
CA2360382A1 (en) 2000-07-20
AU768515B2 (en) 2003-12-18
CN1344167A (zh) 2002-04-10
SK286627B6 (sk) 2009-02-05
PT1140168E (pt) 2002-11-29
ATE286745T1 (de) 2005-01-15
CZ302801B6 (cs) 2011-11-16
US20120003232A1 (en) 2012-01-05
DK1230932T3 (da) 2005-04-25
SI1230932T1 (en) 2005-06-30
DK1140168T3 (da) 2002-09-30
IS5998A (is) 2001-07-10
CN1188169C (zh) 2005-02-09
WO2000041722A1 (de) 2000-07-20
SK9642001A3 (en) 2002-03-05
EP1140168B1 (de) 2002-06-26
PT1230932E (pt) 2005-04-29
HRP20010526A2 (en) 2002-08-31
US7691372B2 (en) 2010-04-06
KR100771752B1 (ko) 2007-10-30
EP1140168A1 (de) 2001-10-10
MXPA01007148A (es) 2002-03-27
ES2177509T3 (es) 2002-12-16
HUP0200527A2 (en) 2002-06-29
IL144265A (en) 2006-08-20
IL144265A0 (en) 2002-05-23
EP1230932B1 (de) 2005-01-12
EP1230932A2 (de) 2002-08-14
DE50000243D1 (de) 2002-08-01
NO20013093L (no) 2001-09-10
NO329917B1 (no) 2011-01-24
AU2796400A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
CR8231A (es) Anticuerpos rg1 y uso de los mismos
BR0114646A (pt) anticorpos anti-lt-beta-r humanizados
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
ATE303161T1 (de) Humanisierung von anti-carcinoembryonalen antigen anti-idiotypischen antikörper und dessen verwendung als tumorvakzin und zur markierung
TR200001253T2 (tr) Tümöre özel antijenler
NO20012135L (no) Forsterkede vaksiner
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
DE69720065D1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
NO20020615D0 (no) Vaksine
UY26170A1 (es) Antigeno (c42) asociados a tumores
BR0007814A (pt) Uso de anticorpos para a vacinação contra câncer
AR023794A1 (es) Antigeno asociado con tumores
UY26127A1 (es) Antígeno asociado con tumores
AR020765A1 (es) Anticuerpos monoclonales humanos contra el antigeno de tumor uk114 y celulas de linfocitos e hibridomas para su produccion
CY1114280T1 (el) Αντισωματα ανταγωνιστων των κυτοκινων θηλαστικων ή οι υποδοχεις τους για την αγωγη της αλλεργιας
CY1108864T1 (el) Ενωσεις για ανοσοθεραπεια και διαγνωση φυματιωσης και μεθοδοι χρησεις τους